RoosterBio, Inc.– Pioneering a New Era in the Regenerative Medicine Manufacturing Supply Chain

“We utilize our core products and expertise to help develop cell-based therapies with commercially-viable bio-manufacturing processes, right-sized to our customers’ needs.”

Regenerative medicine is one of the most fascinating fields in medical science that is used to treat a range of diseases and conditions. Enormous investment is poured in with the hope for fruitful results. Promising outcomes of the research suggest the huge medical potential and the positive impacts on the economy and health care system. Regenerative medicine primarily focuses on the replacement and regeneration of tissues or organs. Moving beyond the scope of traditional transplantation, it is the intersection of various technological approaches including cell and gene therapy, stem cell transplantation, and tissue engineering.

We’re pleased to present RoosterBio, Inc.

RoosterBio, a pioneering regenerative medicine firm, is mainly focused on the simplification of translating Cell Therapy and Tissue Engineering technologies into the clinic and onto the market. The firm primarily aims at designing products that quicken the pace of research and development --to help build a robust and sustainable Regenerative Medicine industry, which will lead to more rapid and wide-spread implementation of life-saving therapies.

The company was founded in 2013 and is headquartered in Frederick, Maryland.

In Conversation with Margot Connor, CEO of RoosterBio

What was the reason behind the genesis of RoosterBio, Inc.?

RoosterBio was founded with the vision to de-bottleneck and revolutionize the regenerative medicine industry. The firm started shipping cell and media products to customers and launched cGMP versions of their innovative MSC (mesenchymal stem/stromal systems). bioprocess systems in the year 2014 and has expanded to 60 employees with 300+ customers worldwide. The company is industrializing the regenerative medicine supply chain and enabling commercially relevant manufacturing for cell-based clinical products.

A well-defined mission and vision statement is the most important phenomenon for any business. Can you explain your M&V statements in brief?

Our mission is to fuel the rapid commercialization of scalable regenerative cures. Our vision is a world where safe and effective regenerative medicine cures are rapidly developed and widely available on a global scale, to benefit the lives of patients in need.

To me, our mission, vision, and values are personal, but the goal is to make it personal for everyone. Our values are important to us. It’s who we are and how we live. We are all trying to get better. Articulating these values in our leadership team is putting a name to how we live. It’s the fabric of this company. It’s not just words on a wall.

What is your greatest fear and how do you overcome it?

I don’t have one long-standing fear that’s plagued me my whole life. Fear is a natural part of humanity. We all have it, in one way or another so I don’t try to shy away from it. I am inspired by Eleanor Roosevelt’s quote: “Do one thing every day that scares you.” It reminds me to see the incredible possibilities that shatter the boundaries you thought were around you. Once you do this, you begin to see more and more things that you are capable of that you never thought possible. At the end of the day, if something really scares you, do it. For me, once you accomplish that, the experience leaves a huge impact and a sense of accomplishment.

What would you say was the single most influential factor in your business’ success?

I think the single most influential factor in the success of our business was the tremendous unmet need in the market that no one was filling. There was a significant market dislocation in cellular raw material supply that no one was addressing. No one dream that there could be a solution for Regenerative Medicine like we have delivered. We happened to have the right people, technology platform, and business model at the right time.  We are leveraging our unique business model approach within a different area of the supply chain. I think it is the dawn of a new day within Regenerative Medicine manufacturing.

What other leaders do you look up to, and why?

For me, it’s much more personal than just picking a leader that I’ve read about. I don’t put people on pedestals – we are all fallible. I can point to those leaders/mentors in my career that caused me to make different decisions, take thoughtful risks, and take leaps. Some of them were fairly steep cliffs. My collective mentors inspired me to take risks and stretch beyond all boundaries.

What do you hope to accomplish in the long run?

In the long run, I want to be able to fulfill our mission and vision by enabling the rapid commercialization of regenerative medicine cures. I will be happy once there are thousands of patients being treated with therapeutic products that RoosterBio supplies the living cells.

Moreover, from a company perspective, we are focusing on expanding our business model globally. I am looking forward to meeting the challenges of the unique market dynamics in new geographies and how our business model translates into these areas. We are focused on key market segments and continue to develop solutions for some of the most promising areas within regenerative medicine. We’re focused on scaling our organization, including opportunities for vertical integrations.

The Ardent Visionary Behind the Success of RoosterBio, Inc

Margot Connor is the Chief Executive Officer of RoosterBio, Inc. She brings an overall experience of 25 years of diversified Life Science industry which includes executive-level accountability for business operations, corporate development, and M&A.

Through Ms. Connor’s leadership, revenues have grown approximately 20-fold since the company’s inception in 2014, while employee numbers have grown from 6 to over 60 FTE. Ms. Connor also led all fundraising activities and has coordinated two successful venture capital rounds and a strategic-led mid-round investment, which has fueled RoosterBio’s rapid growth. The company has soared in value since its founding, though it’s her approachability as a leader that inspires the employees and colleagues alike who agree she is the calm in the storm and leads by example. Prior to this, she led the global growth of several businesses, which included P&L responsibility. Ms. Connor has held senior positions in business management, strategic marketing, and business development with companies such as FMC, Lonza, Chr. Hansen, and Unilever. She holds a Bachelor of Science degree in Textile Chemistry/Marketing from the University of Maryland.

“We are leveraging our unique business model approach within a different area of the supply chain. I think it is the dawn of a new day within Regenerative Medicine manufacturing.”